While exploring cyclin G associated kinase (GAK) as a potential collateral target to treat chordoma, we identified a series of potent EGFR inhibitor starting points based on the 4-anilinoquinazoline scaffold, exemplified by 110,12. This evidence concerns the gene EGFR and chordoma.